Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sean D Sullivan

Showing results (121-130 of 325) with videos related to

Pageof 33
Sort By:
Journal of Managed Care & Specialty Pharmacy|September 12, 2025
Selected drugs, therapeutic alternatives, and price benchmarks for IPAY 2027 Medicare drug price negotiationSean D Sullivan, Emma M Cousin, Kevin H Li, et al.
Journal of Pain and Symptom Management|August 20, 2018
Depression and Health Care Utilization at End of Life Among Older Adults With Advanced Non-Small-Cell Lung CancerCara L McDermott, Aasthaa Bansal, Scott D Ramsey, et al.
International Journal of Geriatric Psychiatry|September 17, 2010
Assessing the cost-effectiveness of the rivastigmine transdermal patch for Alzheimer's disease in the UK using MMSE- and ADL-based modelsBalázs Nagy, Alan Brennan, Agnes Brandtmüller, et al.
JAMA|December 5, 2023
Reimbursement to Pharmacies for Generic Drugs by Medicare Part D SponsorsInmaculada Hernandez, Nico Gabriel, Anna Kaltenboeck, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|August 18, 2024
Integrating Price Benchmarks and Comparative Clinical Effectiveness to Inform the Medicare Drug Price Negotiation ProgramSean D Sullivan, Olivier J Wouters, Emma M Cousin, et al.
American Journal of Alzheimer'S Disease and Other Dementias|March 21, 2013
The validity of dependence as a health outcome measure in Alzheimer's diseaseD Eldon Spackman, Srikanth Kadiyala, Peter J Neumann, et al.
Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy|February 26, 2025
Defining a Framework for Sustainable Global Biosimilars Markets Using Findings from a Targeted Literature ReviewJoshua A Roth, Victoria W Dayer, Mireia Jofre-Bonet, et al.
Applied Health Economics and Health Policy|June 29, 2019
Treatment Patterns, Overall Survival, and Total Healthcare Costs of Advanced Merkel Cell Carcinoma in the USALotte Steuten, Vincent Garmo, Hemant Phatak, et al.
Current Alzheimer Research|December 20, 2011
Measuring Alzheimer disease progression with transition probabilities: estimates from NACC-UDSD Eldon Spackman, Srikanth Kadiyala, Peter J Neumann, et al.
Journal of Managed Care & Specialty Pharmacy|April 27, 2026
Patient out-of-pocket costs and rheumatology biosimilar competitionVictoria W Dayer, Ryan N Hansen, Joshua Roth, et al.
Pageof 33

Showing results (121-130 of 325) with videos related to

Sort By:
Pageof 33
Journal of Managed Care & Specialty Pharmacy|September 12, 2025
Selected drugs, therapeutic alternatives, and price benchmarks for IPAY 2027 Medicare drug price negotiationSean D Sullivan, Emma M Cousin, Kevin H Li, et al.
Journal of Pain and Symptom Management|August 20, 2018
Depression and Health Care Utilization at End of Life Among Older Adults With Advanced Non-Small-Cell Lung CancerCara L McDermott, Aasthaa Bansal, Scott D Ramsey, et al.
International Journal of Geriatric Psychiatry|September 17, 2010
Assessing the cost-effectiveness of the rivastigmine transdermal patch for Alzheimer's disease in the UK using MMSE- and ADL-based modelsBalázs Nagy, Alan Brennan, Agnes Brandtmüller, et al.
JAMA|December 5, 2023
Reimbursement to Pharmacies for Generic Drugs by Medicare Part D SponsorsInmaculada Hernandez, Nico Gabriel, Anna Kaltenboeck, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|August 18, 2024
Integrating Price Benchmarks and Comparative Clinical Effectiveness to Inform the Medicare Drug Price Negotiation ProgramSean D Sullivan, Olivier J Wouters, Emma M Cousin, et al.
American Journal of Alzheimer'S Disease and Other Dementias|March 21, 2013
The validity of dependence as a health outcome measure in Alzheimer's diseaseD Eldon Spackman, Srikanth Kadiyala, Peter J Neumann, et al.
Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy|February 26, 2025
Defining a Framework for Sustainable Global Biosimilars Markets Using Findings from a Targeted Literature ReviewJoshua A Roth, Victoria W Dayer, Mireia Jofre-Bonet, et al.
Applied Health Economics and Health Policy|June 29, 2019
Treatment Patterns, Overall Survival, and Total Healthcare Costs of Advanced Merkel Cell Carcinoma in the USALotte Steuten, Vincent Garmo, Hemant Phatak, et al.
Current Alzheimer Research|December 20, 2011
Measuring Alzheimer disease progression with transition probabilities: estimates from NACC-UDSD Eldon Spackman, Srikanth Kadiyala, Peter J Neumann, et al.
Journal of Managed Care & Specialty Pharmacy|April 27, 2026
Patient out-of-pocket costs and rheumatology biosimilar competitionVictoria W Dayer, Ryan N Hansen, Joshua Roth, et al.
Pageof 33